Donepezil, rivastigmine, galantamine and memantine for ...

154
References
22. Di Carlo A, Baldereschi M, Amaducci L, Lepore V,
Bracco L, Maggi S, et al. Incidence of dementia,
Alzheimer’s disease, and vascular dementia in
Italy. The ILSA Study. J Am Geriatr Soc 2002;
50:41–8.
23. Kukull WA, Higdon R, Bowen JD, McCormick WC,
Teri L, Schellenberg GD, et al. Dementia and
Alzheimer disease incidence: a prospective cohort
study. Arch Neurol 2002;59:1737–46.
24. Fratiglioni L, Launer LJ, Andersen K, Breteler MM,
Copeland JR, Dartigues JF, et al. Incidence of
dementia and major subtypes in Europe: a
collaborative study of population-based cohorts.
Neurologic Diseases in the Elderly Research
Group. Neurology 2000;54(Suppl 5):Suppl-5.
25. Andersen K, Launer LJ, Dewey ME, Letenneur L,
Ott A, Copeland JR, et al. Gender differences in
the incidence of AD and vascular dementia: The
EURODEM Studies. EURODEM Incidence
Research Group. Neurology 1999;53:1992–7.
26. Holmes C, Cooper B, Levy R. Dementia known to
mental health services: first findings of a case
register for a defined elderly population. Int J
Geriatr Psychiatry 2004;10:875–81.
27. Banerjee S. Services for older adults. In
Thornicroft.G, Szmukler G, editors. Textbook of
community psychiatry. London: Oxford University
Press; 2001. pp. 381–96.
28. Neal M, Briggs M. Validation therapy for
dementia. Cochrane Database Syst Rev 2003;
(3):CD001394.
29. Grasel E, Wiltfang J, Kornhuber J. Non-drug
therapies for dementia: an overview of the current
situation with regard to proof of effectiveness.
Dement Geriatr Cogn Disord 2003;15:115–25.
30. NICE Technology Appraisal Guidance – No. 19.
Guidance on the use of donepezil, rivastigmine and
galantamine for the treatment of Alzheimer’s disease.
London: NICE; 2003.
31. Lindesay J, Marudkar M, van Diepen E, Wilcock G.
The second Leicester survey of memory clinics in
the British Isles. Int J Geriatr Psychiatry 2002;
17:41–7.
32. Department of Health. National Service Framework
for Older People. London: Department of Health;
2001.
33. Phipps AJ, O’Brien JT. Memory clinics and clinical
governance – a UK perspective. Int J Geriatr
Psychiatry 2002;17:1128–32.
34. Marshall M. The challenge of looking after people
with dementia (editorial). BMJ 2001;323:410–11.
35. Alzheimer’s Disease Society. Community care
assessment. URL: http://www.alzheimers.org.uk/
After_diagnosis/PDF/418_communityAssess.pdf.
Accessed 18 June 2004.
36. Ballard C, Fossey J, Chithramohan R, Howard R,
Burns A, Thompson P, et al. Quality of care in
private sector and the NHS facilities for people
with dementia: cross sectional survey. BMJ 2001;
323:426–7.
37. Becker RE. Therapy of the cognitive deficit in
Alzheimer’s disease: the cholinergic system. In
Becker RE, Giacobini E, editors. Cholinergic basis
for Alzheimer therapy. Boston; MD: Birkhauser;
1991.
38. CRD. Undertaking systematic reviews of research on
effectiveness. 4. York: Centre for Reviews and
Dissemination; 2001.
39. Drummond M, Jefferson TO. Guidelines for
authors and peer reviewers of economic
submissions to the BMJ. The BMJ Economic
Evaluation Working Party. BMJ 1996;313:275–83.
40. Alderson P, Green S, Higgins J, editors. Cochrane
reviewers’ handbook 4.2.2 [updated March 2004].
In The Cochrane Library, Issue 1. Chichester:
John Wiley; 2004.
41. Gauthier S, Feldman H, Hecker J, Vellas B,
Emir B, Subbiah P, et al. Functional, cognitive and
behavioral effects of donepezil in patients with
moderate Alzheimer’s disease. Curr Med Res Opin
2002;18:347–54.
42. Feldman H, Gauthier S, Hecker J, Vellas B,
Subbiah P, Whalen E, et al. A 24-week,
randomized, double-blind study of donepezil in
moderate to severe Alzheimer’s disease [published
erratum appears in Neurology 2001;57:2153].
Neurology 2001;57:613–20.
43. AD2000 Collaborative Group. Long-term
donepezil treatment in 565 patients with
Alzheimer’s disease (AD2000): randomised
double-blind trial. Lancet 2004;363:2105–15.
44. Homma A, Takeda M, Imai Y, Udaka F,
Hasegawa K, Kameyama M, et al. Clinical efficacy
and safety of donepezil on cognitive and global
function in patients with Alzheimer’s disease:
a 24-week, multicenter, double-blind, placebocontrolled
study in Japan. Dement Geriatr Cogn
Disord 2000;11:299–313.
45. Krishnan KR, Charles HC, Doraiswamy PM,
Mintzer J, Weisler R, Yu X, et al. Randomized,
placebo-controlled trial of the effects of donepezil
on neuronal markers and hippocampal volumes in
Alzheimer’s disease. Am J Psychiatry 2003;
160:2003–11.
46. Mohs RC, Doody RS, Morris JC, Ieni JR,
Rogers SL, Perdomo CA, et al. A 1-year, placebocontrolled
preservation of function survival study
of donepezil in AD patients [published erratum
appears in Neurology 2001;57:1942]. Neurology
2001;57:481–8.
47. Winblad B, Engedal K, Soininen H, Verhey F,
Waldemar G, Wimo A, et al. A 1-year, randomized,